19 May 2013
Keywords: remicade, gains, fda, priority, cd, centocor, infliximab
Article | 08 April 2002
Centocor's Remicade (infliximab) has been designated for priority reviewby the US Food and Drug Administration as a monotherapy for inducing
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 April 2002
1 April 2002
17 May 2013
© 2013 thepharmaletter.com